156 related articles for article (PubMed ID: 26199245)
1. [Study on the Antiemetic Effects of Aprepitant in Patients with Lung Cancer Receiving Chemotherapy with Carboplatin].
Hatsuyama T; Umehara K; Wakamoto A; Sato H
Gan To Kagaku Ryoho; 2015 Jun; 42(6):725-9. PubMed ID: 26199245
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
5. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T
Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the antiemetic effect of aprepitant in lung cancer patients receiving carboplatin-based chemotherapy using the Functional Living Index-Emesis questionnaire].
Nagata S; Yatera K; Tokuyama S; Yamasaki K; Nishida C; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):335-9. PubMed ID: 24743279
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
11. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
Uchino J; Hirano R; Tashiro N; Yoshida Y; Ushijima S; Matsumoto T; Ohta K; Nakatomi K; Takayama K; Fujita M; Nakanishi Y; Watanabe K
Asian Pac J Cancer Prev; 2012; 13(8):4187-90. PubMed ID: 23098425
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
14. Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.
Koshiyama M; Matsumura N; Imai S; Yamanoi K; Abiko K; Yoshioka Y; Yamaguchi K; Hamanishi J; Baba T; Konishi I
Med Sci Monit; 2017 Feb; 23():826-833. PubMed ID: 28198358
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
[TBL] [Abstract][Full Text] [Related]
17. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]